A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
Published in
Prostate Cancer and Prostatic Diseases, January 2022
Pharmacology, Toxicology and Pharmaceutical Science
2
6%
Biochemistry, Genetics and Molecular Biology
2
6%
Nursing and Health Professions
2
6%
Veterinary Science and Veterinary Medicine
1
3%
Other
1
3%
Unknown
22
63%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2026.
All research outputs
#1,527,407
of 32,911,318 outputs
Outputs from Prostate Cancer and Prostatic Diseases
#82
of 1,467 outputs
Outputs of similar age
#31,305
of 561,451 outputs
Outputs of similar age from Prostate Cancer and Prostatic Diseases
#2
of 44 outputs
Altmetric has tracked 32,911,318 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,467 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 561,451 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.
